BCG Vaccine-associated Complications in a Large Cohort of Children With Combined Immunodeficiencies Affecting Cellular and Humoral Immunity

Waleed Al-Herz 1 2, Entesar H Husain 1, Mehdi Adeli 3, Tariq Al Farsi 4, Suleiman Al-Hammadi 5 6, Amna Ali Al Kuwaiti 7, Maryam Al-Nesf 8, Nashat Al Sukaiti 4, Salem Al-Tamemi 9, Hiba Shendi 7

Affiliations

01 November 2022

-

doi: 10.1097/INF.0000000000003678

Abstract

Aims: To present the details of Bacillus Calmette-Guérin (BCG)-vaccine associated complications (VACs) in combined immunodeficiencies (CID) patients.

Methods: Five centers participated in this retrospective study and completed a data form, which included general patients' information, clinical and laboratory data.

Results: Among 236 CID patients, 127 were BCG vaccinated. 41.9% of patients with family history of CID and 17.1% who were diagnosed by screening were BCG vaccinated. Twenty-three patients (18.1%) developed BCG-VACs. The median age of VACs was 6 months and the median time from vaccination to complications was 6 months. The highest rate of BCG-VACs was recorded in patients receiving the Russian BCG strain compared to the Tokyo and Danish strains. Univariate analysis of T-lymphocyte subsets showed increased odds of BCG complications in patients with CD3+, CD4+, and CD8+ counts of ≤250 cells/µL. Only CD8 + count ≤250 cells/µL had increased such odds on multivariate analysis. VACs were disseminated in 13 and localized in 10 patients. Localized complication occurred earlier after vaccination (median: 4 months) compared with disseminated ones (median: 7 months). There were no significant associations between sex, administered vaccine strain, serum immunoglobulins levels, lymphocyte subsets counts, and the chance of having either localized or disseminated BCG-related complications.

Coclusions: Although contraindicated, many patients with CID continue to be vaccinated with BCG. Low CD8 + count is a risk factor for BCG-related complications and localized complications occurred earlier than disseminated ones. Considerations should be undertaken by health care authorities especially in countries with high incidence of CID to implement newborn screening, delay the time of BCG vaccine administration beyond 6 months of age and to use the relatively safer strains like the Danish and Tokyo ones.

Conflict of interest statement

The authors have no funding or conflicts of interest to disclose.

Similar articles

Primary Immunodeficiency Diseases and Bacillus Calmette-Guérin (BCG)-Vaccine-Derived Complications: A Systematic Review.

Fekrvand S, Yazdani R, Olbrich P, Gennery A, Rosenzweig SD, Condino-Neto A, Azizi G, Rafiemanesh H, Hassanpour G, Rezaei N, Abolhassani H, Aghamohammadi A.J Allergy Clin Immunol Pract. 2020 Apr;8(4):1371-1386. doi: 10.1016/j.jaip.2020.01.038. Epub 2020 Jan 30.PMID: 32006723

Bacille Calmette-Guerin (BCG) complications in children with severe combined immunodeficiency (SCID).

Barkai G, Somech R, Stauber T, Barziali A, Greenberger S.Infect Dis (Lond). 2019 Aug;51(8):585-592. doi: 10.1080/23744235.2019.1628354. Epub 2019 Jun 17.PMID: 31204539

DISSEMINATED BACILLUS-CALMETTE-GUÉRIN INFECTIONS AND PRIMARY IMMUNODEFICIENCY DISORDERS IN SINGAPORE: A SINGLE CENTER 15-YEAR RETROSPECTIVE REVIEW.

Ong RYL, Chan SB, Chew SJ, Liew WK, Thoon KC, Chong CY, Yung CF, Sng LH, Tan AM, Bhattacharyya R, Jamuar SS, Lim JY, Li J, Nadua KD, Kam KQ, Tan NW.Int J Infect Dis. 2020 Aug;97:117-125. doi: 10.1016/j.ijid.2020.05.117. Epub 2020 Jun 2.PMID: 32497805 Review.

Antimycobacterial prophylaxis regarding Bacillus Calmette-Guérin -associated complications in children with primary immunodeficiency.

Ozsezen B, Yalçın E, Ademhan Tural D, Sunman B, Nayır Buyuksahin H, Guzelkas İ, Alboga D, Aytekin ES, Esenboga S, Emiralioglu N, Cagdas D, Doğru D, Özçelik U, Tezcan I, Kiper N.Respir Med. 2022 Aug-Sep;200:106919. doi: 10.1016/j.rmed.2022.106919. Epub 2022 Jun 16.PMID: 35779416

Cutaneous complications of BCG vaccination in infants with immune disorders: two cases and a review of the literature.

Antaya RJ, Gardner ES, Bettencourt MS, Daines M, Denise Y, Uthaisangsook S, Buckley RH, Prose NS.Pediatr Dermatol. 2001 May-Jun;18(3):205-9. doi: 10.1046/j.1525-1470.2001.018003205.x.PMID: 11437999 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Tran V, Liu J, Behr MA. BCG vaccines. Microbiol Spectr. 2014;2:MGM2–0028.
  2.  
    1. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271:698–702.
  3.  
    1. Fine PEM, Carneiro IAM, Milstien JB, et al. Issues relating to the use of BCG in immunization programmes: a discussion document. World Health Organization WHO/V&B/99.23. 1999. WHO_V_B_99.23.pdf/. Accessed on May 30, 2022.
  4.  
    1. Nicol M, Eley B, Kibel M, et al. Intradermal BCG vaccination-adverse reactions and their management. S Afr Med J. 2002;92:39–42.
  5.  
    1. Tangye SG, Al-Herz W, Bousfiha A, et al. The Ever-Increasing Array of Novel Inborn Errors of Immunity: An Interim Update by the IUIS Committee. J Clin Immunol. 2021;41:666–679.
  6.  
    1. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies Expert Committee. J Clin Immunol. 2020;40:24–64.
  7.  
    1. Fekrvand S, Yazdani R, Olbrich P, et al. primary immunodeficiency diseases and bacillus calmette-guérin (BCG)-vaccine-derived complications: A systematic review. J Allergy Clin Immunol Pract. 2020;8:1371–1386.
  8.  
    1. Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks and vaccination policies. J Allergy Clin Immunol. 2014;133:1134–1141.
  9.  
    1. Griffith LM, Cowan MJ, Notarangelo LD, et al. Workshop Participants. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol. 2009;124:1152–60.e12.
  10.  
    1. Sadeghi-Shabestari M, Rezaei N. Disseminated bacilli Calmette-Guérin in Iranian children with severe combined immunodeficiency. Int J Infect Dis. 2009;13:e420–e423.
  11.  
    1. Cocchi N, Jacobsen EM, Hoenig M, et al. BCG disease in SCID: Three decades of experience in a pediatric transplant center. J Clin Immunol. 2022;42:195–198.
  12.  
    1. Mazzucchelli JTL, Bonfim C, Castro GG, et al. Severe combined immunodeficiency in Brazil: management, prognosis, and BCG-associated complications. J Investig Allergol Clin Immunol. 2014;24:184–191.
  13.  
    1. Bernatowska E, Skomska-Pawliszak M, Wolska-Kuśnierz B, et al. BCG moreau vaccine safety profile and NK Cells-double protection against disseminated BCG infection in retrospective study of BCG vaccination in 52 polish children with severe combined immunodeficiency. J Clin Immunol. 2020;40:138–146.
  14.  
    1. Waeckerle-Men Y, Kotkowska ZK, Bono G, et al. Photochemically-mediated inflammation and cross-presentation of Mycobacterium bovis BCG proteins stimulates strong CD4 and CD8 T-cell responses in mice. Front Immunol. 2022;13:815609.
  15.  
    1. Basile JI, Liu R, Mou W, et al. Mycobacteria-Specific T cells are generated in the lung during mucosal BCG immunization or infection with mycobacterium tuberculosis . Front Immunol. 2020;11:566319.
  16.  
    1. Lutwama F, Kagina BM, Wajja A, et al. Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants. J Infect Dis. 2014;209:887–897.
  17.  
    1. Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, et al. The BCG Vaccine for COVID-19: first verdict and future directions. Front Immunol. 2021;8:632478.
  18.  
    1. World Health Organization (WHO). Consultation on the Characterization of BCG strains. 2003. Available at: Microsoft Word - Report.WHO Consultation.BCG strains.doc . Accessed on May 30, 2022.
  19.  
    1. Lagranderie MR, Balazuc a M, Deriaud E, et al. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun. 1996;64:1–9.

Page Navigation